Welcome to Dividends Inside
Welcome to Dividends Inside!

The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.

Evommune, Inc.

EVMN
$22.28 (+ $1.16 + 5.49%)
Last updated: 2026-05-21 07:43 UTC
EVMN Metrics
Exchange
🇺🇸 NYSE XNYS
New York Stock Exchange, Inc.United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS30054Y1073
Market Price22.28
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-2.09
Market Cap$556.2M
Book Value-117.78
Price to Book-0.15
BetaN/A
52w High24.03
52w Low13.88
Next Earnings DateN/A
About the Company
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Price History